2025-08-12
Tofacitinib citrate est innovative Janus Kinase (Jak) inhibitor quod habet reversed curatio de pluribus autoimmune conditionibus. Hoc comprehensive dux explorat orci applications, pharmacological mechanism, dosis formae et salus profileTofacitInib citrate, Providemus curis professionals cum essential notitia de hoc breakthrough medication developed aRun'an Pharmaceutical.
TofacitInib citrateNumquid FDA-probatus pro multiple therapeutica indicia cum probata efficacia in:
I. Rheumatoid Arthritis (RA)Moderare gravibus active ra in adultis
MethotRexate combination et Monotherapy
Reduces iuncturam tumor et progressionem structural damnum
Active Psa in aegris cum sufficiens responsum ad DCards
Amplio enthesitis et dactylitis
Moderare gravibus active UC
Inductionem et sustentationem remissionis
Ankylosing spondylitis
ALPECIA Areata
Iuvenalibus idiopathic arthritis
Indicium | Dosage forma | Commendatur dose | Curatio |
---|---|---|---|
Rheumatoid arthritis | Tablet (5mg) | 5mg bis cotidie | Longinquus |
Psoriatic arthritis | Tablet (5mg) | 5mg bis cotidie | Longinquus |
Ulcerative colitis | Fundo, release (11mg) | 11Mg cum cotidie | Inductio: VIII weeks |
TofacitInib citrateExerit eius medicinales effectus per:
Jak-Stat Semita inhibitionisElectionem inhibitionis de Jak1 et Jak3
Modulation de Cytokine Signaling (II-II, II-IV, I-VII, IL IX, II-XV, II-XXI)
Reductionem de inflammatione mediatores
Minuitur circulating CD16 + / CD56 + NK cellulis
Reduces Serum C, Reactive dapibus (CRP) campester
Moderator matrix metalloproteinase (MMMP) campester
Cellula type | Ecfectio | Volume exitus |
---|---|---|
T cellulis | Reducitur proliferation | Ibant inflammatio |
B cellulis | Limitata activation | Inferius Autoantibody productio |
Macrophages | Inhibuit activation | Reducitur TEXTUS damnum |
Superioris respiratorii tractu infectiones (15-20%)
Capitis (4-7%)
Fluxus (3-5%)
Auctus LDL Cholesterol (10-15%)
✔ Herpesvirus Zosti Reactivation
✔ thromboembolic certe
✔ lymphoma et aliis malignancies
✔ gastrointestinal perforationes
✔ CGMP, certified facilities facilities
✔ stricte qualis imperium valde pharmacopeial signa
✔ comprehensive stabilitatem studiis
✔ Global regulatory obsequio (FDA, Ema, PMDA)
✔ Competitive Morbi cursus sapien pro curis systems
Nam productum notitia, orci notitia, aut societate occasiones:
Sicut dux scientific ad curru'an pharmaceutical cum XX annos experientia in immunomodulatory therapies, ego personaliter praestare qualis et efficaciam nostrorumTofacitInib citrateformulae. Contact nostri Medical Negotiis Team hodie ut de quid possumus sustinere vestri medicinales necessitates.